{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(2)"],"submitter":["Rojulpote C"],"pubmed_abstract":["<h4>Background</h4>We used <sup>18</sup>F-sodium fluoride (NaF) to assess early atherosclerosis in the global heart in asymptomatic individuals with a coronary calcium score of zero and without a formal diagnosis of hypertension. We hypothesized that these individuals might present with subclinical atherosclerosis that correlates with systolic, diastolic and mean arterial pressure (SBP, DBP, and MAP).<h4>Methods</h4>We identified 20 asymptomatic individuals (41.6 ± 13.8 years, 8 females) from the CAMONA trial with C-reactive protein ≥3 mg/L, no smoking history, diabetes (fasting blood glucose <126 mg/dl) and dyslipidemia per the Adult Treatment Panel III Guidelines: untreated LDL <160 mg/dL, total cholesterol <240 mg/dL, HDL >40 mg/dL. All underwent PET/CT imaging 90 minutes after NaF inje"],"journal":["American journal of cardiovascular disease"],"pagination":["101-107"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7364275"],"repository":["biostudies-literature"],"pubmed_title":["NaF-PET/CT global assessment in detecting and quantifying subclinical cardiac atherosclerosis and its association with blood pressure in non-dyslipidemic individuals."],"pmcid":["PMC7364275"],"pubmed_authors":["Bravo PE","Borja AJ","Gonuguntla K","Alavi A","Asadollahi S","Werner TJ","Karambelkar P","Raynor WY","Zhang V","Gerke O","Patil S","Bhattaru A","Seraj SM","Hoilund-Carlsen PF","Rojulpote C"],"additional_accession":[]},"is_claimable":false,"name":"NaF-PET/CT global assessment in detecting and quantifying subclinical cardiac atherosclerosis and its association with blood pressure in non-dyslipidemic individuals.","description":"<h4>Background</h4>We used <sup>18</sup>F-sodium fluoride (NaF) to assess early atherosclerosis in the global heart in asymptomatic individuals with a coronary calcium score of zero and without a formal diagnosis of hypertension. We hypothesized that these individuals might present with subclinical atherosclerosis that correlates with systolic, diastolic and mean arterial pressure (SBP, DBP, and MAP).<h4>Methods</h4>We identified 20 asymptomatic individuals (41.6 ± 13.8 years, 8 females) from the CAMONA trial with C-reactive protein ≥3 mg/L, no smoking history, diabetes (fasting blood glucose <126 mg/dl) and dyslipidemia per the Adult Treatment Panel III Guidelines: untreated LDL <160 mg/dL, total cholesterol <240 mg/dL, HDL >40 mg/dL. All underwent PET/CT imaging 90 minutes after NaF inje","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2025-05-29T20:51:32.759Z","creation":"2020-11-19T16:52:53Z"},"accession":"S-EPMC7364275","cross_references":{"pubmed":["32685267"]}}